Molecular markers in transitional cell carcinoma of the bladder: New insights into mechanisms and prognosis

Indian Journal of Urology

Volumn 24, Issue 1, 2008, Pages 61-67

  Ehdaie, Behfar ^a   Theodorescu, Dan ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Angiogenesis; Biomarkers; Bladder cancer; Carcinogenesis; Cell cycle regulators; Loss of heterozygosity; Molecular markers; Prognosis; Urothelial carcinoma

Indexed keywords

EID: 38549090082     PISSN: 09701591     EISSN: None     Source Type: Journal    
DOI: 10.4103/0970-1591.38606     Document Type: Article

References (85)

1. Beaglehole R, Irwin A, Prentice T. Changing history. The World Health Report: 2004. p. 122.
2. Pelucchi C, Bosetti C, Negri E, Malvezzi M, La Vecchia C. Mechanisms of disease: The epidemiology of bladder cancer. Nat Clin Pract Urol 2006;3:327-40.
3. Heney NM. Naturalhistory of superficial bladder cancer: Prognosticfeatures and long-term disease course. Urol Clin North Am 1992;19:429-33.
4. Holmang S, Hedelin H, Anderstrom C, Johansson SL The relationship among multiple recurrences, progression and prognosis of patients with stages ta and T1 transitional cell cancer of the bladder followed for at least 20 years. JUrol 1995;153:1823-7.
5. May M, Helke C, Nitzke T, Vogler H, Hoschke B. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation. Urol Int 2004;72:103-11.
6. rd, Ohneseit PR Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784-8.
7. Wu XR. Urothelial tumorigenesis: Atale of divergent pathways. Nat Rev Cancer 2005;5:713-25.
8. Knowles MA Molecular subtypes of bladder cancer: Jekyll and hyde or chalk and cheese? Carcinogenesis 2006;27:361-73.
9. Mhawech-Fauceglia P, Cheney BT, Schwaller J. Genetic alterations in urothelial bladder carcinoma: An updated review. Cancer 2006;106:1205-16.
10. Hanahan D, Weinberg RA The hallmarks of cancer. Cell 2000;100:57-70.
11. Smith JA Jr, Labasky SF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages ta, T1 and TIS). J Urol 1999;162:1697-701.
12. Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W, De Mulder P. et al. Chemotherapy for bladder cancer: Treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy and metastatic cancer. Urology 2007;69:62-79.
13. Nieder AM, Brausi M, Lamm D, O'Donnell M, Tomita K, Woo H. et al. Management of stage T1 tumors of the bladder: International consensus panel. Urology 2005;66:108-25.
14. Petrylak D, Faulkner JR, Van Veldhuizen PJ. Evaluation of ZD1839 for advanced transitional cell carcinoma (TCC) of the urothelium: A Southwest Oncology Group trial. Proc Am Soc Clin Oncol 2003;22:403.
15. Weinberg RA Oncogenes, antioncogenes and the molecular bases of multistep carcinogenesis. Cancer Res 1989;49:3713-21.
16. Kurth KH, Denis L, Bouffioux C, Sylvester R, Debruyne FM, Pavone-Macaluso M, et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995;31A:1840-6.
17. Stoehr R, Zietz S, Burger M, Filbeck T, Denzinger S, Obermann EC, et al. Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer. Eur Urol 2005;47:58-63.
18. Obermann EQ Junker K, Stoehr R, Dietmaier W, Zaak D, Schubert J, et al. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH and FISH analyses. J Pathol 2003;199:50-7.
19. Chow NH, Cairns P, Eisenberger CF, Schoenberg MP, Taylor DC, Epstein JI, et al. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer 2000;89:514-8.
20. Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Knuechel R. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 1999;154:721-7.
21. Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstetter A, Hofstaedter F, et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 2002;62:809-18.
22. Kruger S, Mess F, Bohle A, Feller AC. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Int J Oncol 2003;23:41-8.
23. Gschwind A, Fischer OM, Ullrich A The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer 2004;4:361-70.
24. Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, et al. FGFS3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003;63:8108-12.
25. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, et al. Focus on bladder cancer. Cancer Cell 2004;6:111-6.
26. Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. An J Pathol 2001;158:1955-9.
27. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA FGFR3 and ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005;24:5218-25.
28. Oxford G, Thcodorescu D. The role of ras superfamily proteins in bladder cancer progression. J Urol 2003;170:1987-93.
29. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001;61:1265-8.
30. van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boevé ER Jöbsis AC, et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004;64:1911-4.
31. van Rhijn BW Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003;21:1912-21.
32. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001;2:BEVIEWS3005.
33. van Rhijn BW Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003;21:1912-21.
34. Zieger K, Dyrskjot L, Wiuf C, Jensen JL, Andersen CL, Jensen KM, et al. Role of activating fibroblast growth, factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res 2005;11:7709-19.
35. Hernandez S, Lopez-Knowles E, ∐oreta J, Kogevinas M, Jarainillo R, Auorós A, et al. FGFR3 and Tp53 mutations in T1G3transitional bladder carcinomas: Independent distribution and lack of association with prognosis. Clin Cancer Res 2005;11:5444-50.
36. Mhawech-Fauceglia P, Cheney RT, Fischer G, Beck A, Herrmann FR FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol 2006;32:231-7.
37. Dalbagni G, Presti J, Reuter Y, Fair WR, Cordon-Cardo C. Genetic alterations in bladder cancer. Lancet 1993;34286:469-71.
38. Zhang ZT, Pak J, Huang HY, Shapiro E, Sun TT, Pellicer A, et al. Role of ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 2001;20:1973-80.
39. Messing EM, Young TB, Hunt VB, Gilchrist KW, Newton MA, Brain LL, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 1995;45:387-97.
40. Sengupta S, Harris CC. p53: Traffic cop at the crossroads of DNArepair and recombination. Nat Rev Mol Cell Biol 2005;6:44-55.
41. Livingstone LR White A, Sprouse J, Livanos E. Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992;70:923-35.
42. Cordon-Cardo C. Molecular alterations in bladder cancer. Cancer Surv 1998;32:115-31.
43. Ortoft TF, Wolf H. Molecular alterations in bladder cancer. Urol Res 1998;26:223-33.
44. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang ZF, Rosai J, et al. p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns. Int J Cancer 1994;56:347-53.
45. Casetta G, Gontero P, Russo R, Pacchioni D, Tizzani A. p53 expression compared with, other prognostic factors in OMS grade-I stage-ta transitional cell carcinoma of the bladder. Eur Urol 1997;32:229-36.
46. Esrig D, Hmajian D, Groshen S, Freeman JA, Stein JR Chen SC, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-64.
47. Gontero P, Casetta G, Zitella A, Ballario R, Pacchioni D, Magnani C, et al. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol. 2000;38:287-96.
48. Hernandez S, Lopez-Knowles E, ∐oreta J, Kogevinas M, Jarainillo R, Amorós A, et al. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: Independent distribution and lack of association with prognosis, Clin Cancer Res 2005;11:5444-50.
49. Lacombe L, Dalbagni G, Zhang ZF, Cordon-Cardo C, Fair WR, Herr HW, et al. Overexpression of p53 protein in a high-risk population of patients with, superficial bladder cancer before and after bacillus calmette-guerin therapy: Correlation to clinical outcome. J Clin Oncol 1996;14:2646-52.
50. lianes P, Charytonowicz E, Cordon-Cardo C, Fradet Y, Grossman HB, Hemstreet GP, et al. Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer: National cancer institute bladder tumor marker network. Clin Cancer Res 1998;4:1267-71.
51. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, Carrasco JC, et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: The role of G1-S modulators (p53, p21 Waf1, p27kip1, cyclin D1 and cyclin D and proliferation index ki67-MIB). Eur Urol 2004;45:606-12.
52. Lopez-Beltran A, Luque BJ, Alvarez-Kindelan J, Quintero A, Merlo F, Requena MJ, et al. Prognostic factors in survival of patients with stage ta and T1 bladder urothelial tumors: The role of Gl-S modulators (p53, p21Waf1, p27Kp1, cyclin D1 and cyclin D, proliferation index and clinicopathologic parameters. Am J Clin Pathol 2004;122:444-52.
53. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, et al. P53 as a prognostic marker for bladder cancer: A meta-analysis and review. Lancet Oncol 2005;6:678-86.
54. Schmitz-Drager BJ, Goebell PJ, Heydthausen M. p53 immunohistochemistry in bladder cancer, combined analysis: A way to go? Urol Oncol 2000;5:204-10.
55. Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, Dickinson MG, et al. Effect of p21WAF1/QP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998;90:1072-9.
56. Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE Benedict WF, et al. p53, p21, pRB and p.16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004;22:1014-24.
57. Shariat SF, Ashfaq R, Sagalowsky AL Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol. 2007;177:481-7.
58. Genovese C, Trani D, Caputi M, Claudio PP. Cell cycle control and beyond: Emerging roles for the retinoblastoma gene family. Oncogene 2006;25:5201-9.
59. Chellappan SE Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. Cell 1991;65:1053-61.
60. Mtra AP, Lin H, Datar RH, Cote RJ. Molecular biology of bladder cancer: Prognostic and clinical implications. Clin Genitourin Cancer 2006;5:67-77.
61. Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, et al. Combined effects of p53, p21 and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004;22:1007-13.
62. Cote RI, Dunn MD, Chatterjee SJ, Stein JP, Shi SR Tran QC, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998;58:1090-4.
63. Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res 1999;59:3512-7.
64. Garcia del Muro X, Torregrosa A, Munoz J, Castellsagué X, Condom E, Vigués F, et al. Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer. Eur J Cancer 2000;36:357-62.
65. Matsumoto K, Shariat SF, Casella R, Wheeler TM, Slawin KM, Lerner SP. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol 2003;170:2248-52.
66. Popov Z, Gil-Diez de Medina S, Lefrere-Belda MA Hoznek A, Bastuji-Garin S, Abbou CC, et al. Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information. Br J Cancer 2000;83:209-14.
67. Shariat SF, Pahlavan S, Baseman AG, Brown SM Green AE, Wheeler TM, et al. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology 2001;57:60-5.
68. Weidner N, Semple JR Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
69. Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, et al. Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995;87:1603-12.
70. Bernardim S, Fauconnet S, Chabannes E, Henry PC, Adessi G, Bittard H. Serum levels of vascular endothelial growth tactor as a prognostic factor in bladder cancer. J Urol 2001;166:1275-9.
71. Chambers AF, MacDonald IC, Schmidt EE, Koop S, Morris VL, Khokha R, et al. Steps in tumor metastasis: New concepts from intravital videomicroscopy. Cancer Metastasis Rev 1995;14:279-301.
72. Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y, et al. Significant association of Rho/ROCKpathway with invasion and metastasis of bladder cancer. Clin Cancer Res 2003;9:2632-41.
73. Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 2002;62:6418-23.
74. Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson HF Jr. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res 2004;10:3800-6.
75. International Bladder Cancer Nomogram Consortium, Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006;24:3967-72.
76. Aaboe M, Marcussen N, Jensen KM, Thykjaer T, Dyrskjot L, Orntoft TF. Gene expression profiling of noninvasive primary urothelial tumours using microarrays. Br J Cancer 2005;93:1182-90.
77. Aebersold R, Mann M. Mass spectrometry-based proteoinics. Nature 2003;422:198-207.
78. Sanchez-Carbayo M, Cordon-Cardo C. Applications of array technology: Identification of molecular targets in bladder cancer. Br J Cancer 2003;89:2172-7.
79. Habuchi T, Marberger M, Droller MJ, Hemstreet GP 3rd, Grossman HB, Schalken JA et al. Prognostic markers for bladder cancer: International consensus panel on bladder tumor markers. Urology 2005;66:64-74.
80. Wang S, El-Deiry WS. The p53 pathway: Targets for the development of novel cancer therapeutics. Cancer Treat Res 2004;119:175-87.
81. McNeish IA, Bell SJ, Lemoine NR Gene therapy progress and prospects: Cancer gene therapy using tumour suppressor genes. Gene Ther 2004;11:497-503.
82. Thomas CY, Theodorescu D. Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas. World J Urol 2006;24:565-78.
83. Mitra AR Datar BH, Cote SJ. Molecular pathways in invasive bladder cancer: New insights into mechanisms, progression and target identification. J Clin Oncol 2006;24:5552-64.
84. Titus B, Frierson HF Jr, Conaway M, Ching K, Guise T, Chirgwin J, et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 2005;65:7320-7.
85. Smith ND, Rubenstein JN, Eggener SE, Kozloswki JM. The p53 tumor suppressor gene and nuclear protein: Basic science review and relevance in the management of bladder cancer. J Urol 2003;169:1219-28.